Premium
Fluoxetine‐ and Norfluoxetine‐Mediated Complex Drug–Drug Interactions: In Vitro to In Vivo Correlation of Effects on CYP2D6, CYP2C19, and CYP3A4
Author(s) -
Sager J E,
Lutz J D,
Foti R S,
Davis C,
Kunze K L,
Isoherranen N
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2014.50
Subject(s) - pharmacology , cyp3a4 , in vivo , cyp2d6 , dextromethorphan , metabolite , pharmacokinetics , fluoxetine , chemistry , drug interaction , drug , cyp2c19 , active metabolite , omeprazole , cytochrome p450 , in vitro , medicine , biology , enzyme , biochemistry , receptor , serotonin , microbiology and biotechnology
Fluoxetine and its circulating metabolite norfluoxetine comprise a complex multiple‐inhibitor system that causes reversible or time‐dependent inhibition of the cytochrome P450 (CYP) family members CYP2D6, CYP3A4, and CYP2C19 in vitro . Although significant inhibition of all three enzymes in vivo was predicted, the areas under the concentration–time curve (AUCs) for midazolam and lovastatin were unaffected by 2‐week dosing of fluoxetine, whereas the AUCs of dextromethorphan and omeprazole were increased by 27‐ and 7.1‐fold, respectively. This observed discrepancy between in vitro risk assessment and in vivo drug–drug interaction (DDI) profile was rationalized by time‐varying dynamic pharmacokinetic models that incorporated circulating concentrations of fluoxetine and norfluoxetine enantiomers, mutual inhibitor–inhibitor interactions, and CYP3A4 induction. The dynamic models predicted all DDIs with less than twofold error. This study demonstrates that complex DDIs that involve multiple mechanisms, pathways, and inhibitors with their metabolites can be predicted and rationalized via characterization of all the inhibitory species in vitro . Clinical Pharmacology & Therapeutics (2014); 95 6, 653–662. doi: 10.1038/clpt.2014.50